What to Look for in a PLGA Supplier

PLGA is often described with terms and phrases like “bioresorbable”, “biocompatible”, and “tunable”. 

Those terms are accurate, though they share very little about how a specific grade behaves after processing, storage, sterilization, or immersion in a degradation study. A device team still has to determine whether IV shifts during fabrication, whether residual moisture accelerates hydrolysis, and whether two lots with the same nominal LA:GA ratio produce comparable degradation profiles. 

In a medical device program, PLGA may start as a screening material before becoming a controlled input tied to device performance, processing assumptions, regulatory documentation, and long-term supply planning. At that point, supplier evaluation extends beyond whether the right grade is available. The supplier’s team also has to understand how lot consistency, change notification, documentation support, and continuity from development lots to later-stage supply will be managed. 

“Customers should look for a supplier that understands how PLGA characteristics affect device performance, not just how the grade is described in a specification,” says Sean Moore, VP of Sales. “Once teams start generating processing data, degradation data, or regulatory documentation around a specific material, small differences in the polymer can become much harder to dismiss.” 

PLGA performance depends on the polymer chemistry, the processing history, and the controls used during production. A catalog listing can identify candidate grades, though it can’t show whether the selected material can be reproduced, documented, and supplied under the controls the program may need later on. 

Start with the grade, then examine the controls behind it 

Most PLGA evaluations begin with the grade description. The LA ratio, inherent viscosity, end-group chemistry, and supplied form give the team an initial sense of how the material may behave in a device. For example, a 50:50 PLGA will usually be evaluated with different degradation expectations than a higher-lactide grade. A lower-IV material may also respond differently during processing than a higher-IV material. 

Those specifications tend to be the most helpful if the supplier can explain how they’re controlled. For example, in a medical device program, the team needs to understand how the grade is made, how IV is measured, how composition is verified, and how much movement is typical from lot to lot. 

Moore notes that teams should ask how consistently the supplier can control “inherent viscosity or molecular weight, residual monomer, residual solvent, and end-group chemistry from lot to lot.” 

The nominal grade may be the same, while the material history is not. Differences in molecular weight distribution, residual moisture, or residual monomer profile can carry through to processing and degradation data. 

As such, a catalog grade can be useful for initial screening, but it may not answer the next development question. A molded component may show a shift in strength retention after a lot change. A scaffold may lose more molecular weight than expected during fabrication. A coating may release too quickly even though the incoming PLGA meets the stated specification. In those cases, the supplier’s team needs to help determine whether the next step is tighter control of the existing grade, a controlled development lot, or a custom synthesis that changes one material variable at a time. 

A credible supplier should be able to distinguish release specifications from typical values and explain where tighter controls are possible. That information helps the device team decide whether the grade is appropriate for feasibility work, whether it should be evaluated through additional development lots, and/or whether the program needs a more controlled material path before moving toward GMP supply. 

Evaluate PLGA against the device output 

The same PLGA family can be evaluated against very different outputs depending on the device. A suture may be judged by tensile retention and absorption profile. An orthopedic fixation component may put more weight on modulus, fixation strength, dimensional stability, and resorption timing. A drug-eluting coating brings in film formation, coating integrity, drug-polymer compatibility, and release kinetics. A scaffold or 3D-printed implant may depend more on pore stability, water uptake, mass loss, local pH shift, and whether fabrication changes molecular weight before degradation testing begins. 

The supplier evaluation should follow the data the team is trying to interpret. For a fixation device, the discussion may center on strength retention after processing and during degradation. For a coating, the supplier may need to speak to how PLGA chemistry and molecular weight influence film behavior or release profile. For a scaffold, the relevant questions may shift toward degradation timing, porosity retention, and the effect of fabrication on IV before the first in vitro study is run. 

A supplier doesn’t need to predict device performance, though it’s important that they understand how polymer attributes can carry into the measurements a device team is using to make decisions. 

Evaluate research-to-GMP continuity early 

Many PLGA programs begin with research-grade material, which is appropriate during feasibility work, early prototyping, degradation screening, or scaffold development. 

Teams should discuss GMP-grade availability before the selected grade becomes difficult to separate from the design history. After a PLGA has been used in prototypes, processing trials, degradation studies, or early performance testing, the program can start to form around that material. Geometry, process conditions, degradation expectations, and test plans may all become tied to the selected grade. 

Changing suppliers later can introduce a new lot history, residual profile, IV range, process response, documentation package, and qualification burden. Even when the replacement material is technically suitable, the team may need to repeat studies or explain why prior data still applies. This can lead to delays. 

A supplier should be able to describe how its research-grade PLGA relates to a GMP-manufactured version of the same chemistry. Where the two aren’t identical, the differences should be clear enough for the device team to evaluate before the material becomes too challenging to change. 

Quality systems and documentation 

For medical device programs, the supplier’s quality system affects how long a PLGA grade can remain usable as the program advances. 

The documentation burden depends on the application and stage. A research scaffold study may only need basic technical and lot information. Meanwhile, a commercial absorbable implant will bring a different level of scrutiny around traceability, change control, retained samples, release testing, and regulatory documentation. 

A PLGA grade may appear to be acceptable in early testing and then become harder to support as the program moves into quality or regulatory review. At that stage, teams need more than just performance data; they need a clear record of how the material was made, how lots were released and traced, and which changes would require notification. 

“For regulated applications, customers should consider whether the supplier has experience supporting medical device, pharma, or bioresorbable programs,” Moore says. “The expectations around documentation, change control, and traceability are different once the material becomes part of a regulated product.” 

An R&D team may understand why the grade was selected but the next review group needs a documented basis for keeping it: lot history, release testing, traceability, change control, and a certificate of analysis that reflects the attributes the team is actually monitoring. 

A supplier should be able to explain the quality system used for PLGA manufacturing, which attributes appear on the certificate of analysis, how specifications are set, how manufacturing or raw material changes are communicated, and whether the supplier can support quality questionnaires, audits, quality agreements, or regulatory documentation when the program requires it. 

Ask how lot-to-lot consistency is managed 

A single successful lot can provide useful data, though it doesn’t necessarily establish consistency. 

PLGA performance can be sensitive to factors like molecular weight, inherent viscosity, LA ratio, end-group chemistry, residual monomers, moisture, and processing history. Shifts in these attributes may affect degradation behavior, process response, mechanical retention, or release performance. 

During supplier evaluation, the team should understand the following: 

  • what variability is typical for the attributes being monitored 

  • how specifications are established 

  • whether ranges are based on process capability, historical lot data, or customer requirements. 

If the application is sensitive to small shifts in IV, residual moisture, or composition, the supplier should also be able to discuss tighter ranges, development-lot comparisons, and how out-of-trend results are handled. 

Lot consistency becomes easier to judge after the team has data from multiple batches, instead of just one. One lot can make a device or formulation look stable, while the second or third lot starts to show whether the design can tolerate the supplier’s normal material variation. 

If degradation or mechanical data shifts, the polymer may be only part of the root cause. Drying conditions, melt exposure, sterilization, device geometry, and the test method can all move the result. A useful supplier can help determine whether the PLGA lot itself is contributing to the change or whether the team should look elsewhere first. 

Consider processing history, not just polymer availability 

PLGA can change before the finished device ever enters a degradation study. A material that meets the incoming specification may lose molecular weight during extrusion, pick up moisture during handling, or behave differently after sterilization. Those changes can show up later as shifts in strength retention, release behavior, mass loss, or degradation timing. 

The supplier doesn’t need to own the device manufacturer’s process. That said, they should understand how PLGA responds to drying, heat, shear, solvent exposure, and sterilization well enough to help the team interpret shifts in degradation, mechanical, or release data. 

Device teams should ask about recommended handling, storage, drying, thermal exposure, and stability. They should also ask whether the supplier has experience supporting the intended processing route, especially if the program involves extrusion, injection molding, coating, solvent processing, or additive manufacturing. 

Consider custom synthesis when catalog grades stop answering the question 

Custom PLGA is sometimes viewed as a specialized need reserved for later-stage programs. In practice, custom work can become useful once the device team has enough data to see where catalog grades fall short. 

A catalog grade may be close enough for screening and still leave the team with an unresolved problem. If a scaffold loses structure too early, or a coating releases too quickly, moving to the nearest available grade may change several variables at once. That provides challenges, since the team may get a new result without knowing whether the shift came from molecular weight, end-group chemistry, composition, or residuals. 

Custom synthesis can help isolate the variable that matters. The team can make a more informed decision about the eventual material specification instead of interpreting a series of unrelated catalog-grade comparisons. 

Include supply continuity in the evaluation 

PLGA sourcing may start as a purchasing task, but it becomes part of the development plan once lot availability, lead time, or documentation affects study timing. A team running repeated prototype builds, degradation studies, coating trials, or lot comparisons needs material access to be predictable enough that the work is not repeatedly reset by supply gaps. 

“A supplier has to support the program you’re running now and the program you may need to run later,” Moore says. “That means small development quantities, a realistic scale-up path, transparent lead times, and clear communication around manufacturing or quality changes.” 

Domestic manufacturing can reduce delays that show up during active development. The value is not limited to transit time. It can also mean faster access to technical staff, easier coordination with production and quality teams, and a shorter path between identifying a material issue and understanding whether it comes from the lot, the process, or the specification. 

Geography does not compensate for weak technical or quality support. It should be evaluated together with the supplier’s ability to make the material consistently, document it appropriately, and support scale-up. 

Questions to ask a PLGA supplier before the material becomes part of the design history 

Before a PLGA grade becomes embedded in prototypes, degradation studies, process assumptions, or regulatory documentation, teams should ask questions that go beyond availability and nominal specifications. 

  • How are inherent viscosity or molecular weight, residual monomer, residual solvent, moisture, and end-group chemistry controlled from lot to lot? 

  • What analytical data is provided with each lot, and is it sufficient for the team’s development, regulatory, and quality needs? 

  • Can the supplier support both small development quantities and later GMP or commercial supply? 

  • How are manufacturing changes, raw material changes, specification changes, and lead-time changes communicated? 

  • Does the supplier have experience supporting medical device, pharma, or bioresorbable applications? 

  • Can the supplier discuss how PLGA may respond to the intended processing route, including drying, thermal exposure, solvent processing, sterilization, extrusion, molding, coating, or additive manufacturing? 

  • If a catalog grade stops answering the development question, can the supplier support tighter controls, development lots, or custom synthesis? 

The answers don’t need to resolve every development risk at the beginning of the program. They should give the team a clearer view of whether the supplier can support the material as the program moves from early screening into a more controlled development path, though. 

Final considerations 

For early screening, an available PLGA grade may be enough. As the device program advances, the supplier has to support the polymer chemistry, the lot history, the documentation, the manufacturing controls, and the scale-up path that come with continued use of that material. 

The practical question is whether the same PLGA source can still support the program after the material has moved from screening input into the design history.  

 

Back to blog